The spectrum of tuberculosis infection: New perspectives in the era of biologics

Giovanni Delogu, Delia Goletti

Research output: Contribution to journalArticle

Abstract

The risk of developing active tuberculosis (TB) is higher in patients taking immunosuppressive drugs, either as a result of reactivation of a latent TB infection (LTBI) or following a new infection with Mycobacterium tuberculosis (Mtb). We discuss the pathogenesis and spectrum of Mtb infection in light of its implication for the management of patients following biologic regimens. Among recent findings, during LTBI, Mtb can persist in the host for decades, localizing in many tissues and assuming different metabolic states that protect the bacilli from the harsh host immune defenses. Despite the strong host T cell response against Mtb, the bacilli may also replicate and multiply in vivo, and any event impairing immune function may lead to active and uncontrolled bacteria replication and active disease. The classic dichotomy between active and latent disease is being reconsidered in favor of a continuous and dynamic spectrum extending from infection to disease that can coexist in the same individual. This TB spectrum results from the dynamic interaction between the host immune system and the bacilli and can be maintained in equilibrium for decades, although treatments affecting the host immune cells may result in disease reactivation

Original languageEnglish
Pages (from-to)11-16
Number of pages6
JournalJournal of Rheumatology
Volume41
Issue numberSUPPL. 91
DOIs
Publication statusPublished - 2014

Fingerprint

Biological Products
Mycobacterium tuberculosis
Tuberculosis
Bacillus
Infection
Latent Tuberculosis
Mycobacterium Infections
Immunosuppressive Agents
Immune System
Bacteria
T-Lymphocytes
Pharmaceutical Preparations
Therapeutics

Keywords

  • Biologic therapies
  • Latent infection
  • Tuberculosis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

The spectrum of tuberculosis infection : New perspectives in the era of biologics. / Delogu, Giovanni; Goletti, Delia.

In: Journal of Rheumatology, Vol. 41, No. SUPPL. 91, 2014, p. 11-16.

Research output: Contribution to journalArticle

@article{5e065711f7714857811e4e8e3a8db32e,
title = "The spectrum of tuberculosis infection: New perspectives in the era of biologics",
abstract = "The risk of developing active tuberculosis (TB) is higher in patients taking immunosuppressive drugs, either as a result of reactivation of a latent TB infection (LTBI) or following a new infection with Mycobacterium tuberculosis (Mtb). We discuss the pathogenesis and spectrum of Mtb infection in light of its implication for the management of patients following biologic regimens. Among recent findings, during LTBI, Mtb can persist in the host for decades, localizing in many tissues and assuming different metabolic states that protect the bacilli from the harsh host immune defenses. Despite the strong host T cell response against Mtb, the bacilli may also replicate and multiply in vivo, and any event impairing immune function may lead to active and uncontrolled bacteria replication and active disease. The classic dichotomy between active and latent disease is being reconsidered in favor of a continuous and dynamic spectrum extending from infection to disease that can coexist in the same individual. This TB spectrum results from the dynamic interaction between the host immune system and the bacilli and can be maintained in equilibrium for decades, although treatments affecting the host immune cells may result in disease reactivation",
keywords = "Biologic therapies, Latent infection, Tuberculosis",
author = "Giovanni Delogu and Delia Goletti",
year = "2014",
doi = "10.3899/jrheum.140097",
language = "English",
volume = "41",
pages = "11--16",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "SUPPL. 91",

}

TY - JOUR

T1 - The spectrum of tuberculosis infection

T2 - New perspectives in the era of biologics

AU - Delogu, Giovanni

AU - Goletti, Delia

PY - 2014

Y1 - 2014

N2 - The risk of developing active tuberculosis (TB) is higher in patients taking immunosuppressive drugs, either as a result of reactivation of a latent TB infection (LTBI) or following a new infection with Mycobacterium tuberculosis (Mtb). We discuss the pathogenesis and spectrum of Mtb infection in light of its implication for the management of patients following biologic regimens. Among recent findings, during LTBI, Mtb can persist in the host for decades, localizing in many tissues and assuming different metabolic states that protect the bacilli from the harsh host immune defenses. Despite the strong host T cell response against Mtb, the bacilli may also replicate and multiply in vivo, and any event impairing immune function may lead to active and uncontrolled bacteria replication and active disease. The classic dichotomy between active and latent disease is being reconsidered in favor of a continuous and dynamic spectrum extending from infection to disease that can coexist in the same individual. This TB spectrum results from the dynamic interaction between the host immune system and the bacilli and can be maintained in equilibrium for decades, although treatments affecting the host immune cells may result in disease reactivation

AB - The risk of developing active tuberculosis (TB) is higher in patients taking immunosuppressive drugs, either as a result of reactivation of a latent TB infection (LTBI) or following a new infection with Mycobacterium tuberculosis (Mtb). We discuss the pathogenesis and spectrum of Mtb infection in light of its implication for the management of patients following biologic regimens. Among recent findings, during LTBI, Mtb can persist in the host for decades, localizing in many tissues and assuming different metabolic states that protect the bacilli from the harsh host immune defenses. Despite the strong host T cell response against Mtb, the bacilli may also replicate and multiply in vivo, and any event impairing immune function may lead to active and uncontrolled bacteria replication and active disease. The classic dichotomy between active and latent disease is being reconsidered in favor of a continuous and dynamic spectrum extending from infection to disease that can coexist in the same individual. This TB spectrum results from the dynamic interaction between the host immune system and the bacilli and can be maintained in equilibrium for decades, although treatments affecting the host immune cells may result in disease reactivation

KW - Biologic therapies

KW - Latent infection

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=84899797129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899797129&partnerID=8YFLogxK

U2 - 10.3899/jrheum.140097

DO - 10.3899/jrheum.140097

M3 - Article

C2 - 24788995

AN - SCOPUS:84899797129

VL - 41

SP - 11

EP - 16

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - SUPPL. 91

ER -